Arrowhead Pharmaceuticals Inc. (ARWR) Reports Q2 EPS of $0.45

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $0.45, versus $0.41 reported last year. Revenue for the quarter came in at $146.3 million, versus $151.8 million reported last year.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'